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Abstract 
Objective: To identify the prevalence, frequency of use, and effects of analgesic pain management 
strategies used in elite athletes. 
Design: Systematic literature review 
Data Sources: Six databases: Ovid/Medline, SPORTDiscus, CINAHL, Embase, Cochrane Library, and 
Scopus. 
Eligibility criteria for selecting studies: Empirical studies involving elite athletes and focused on the use 
or effects of medications used for pain or painful injury. Studies involving recreational sportspeople or 
those that undertake general exercise were excluded. 
Main Results: Of 70 articles found, the majority examined the frequency with which elite athletes use 
pain medications, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, anesthetics, 
and opioids. A smaller set of studies assessed the effect of medications on outcomes such as pain, 
function, and adverse effects. Oral NSAIDs are reported to be the most common medication, being used 
in some international sporting events by over 50% of athletes. Studies examining the effects of pain 
medications on elite athletes typically involved small samples and lacked control groups against which 
treated athletes were compared. 
Conclusions: Existing empirical research does not provide a sufficient body of evidence to guide athletes 
and healthcare professionals  in making analgesic medication treatment decisions. Based on the 
relatively robust evidence regarding the widespread use of NSAIDs, clinicians and policymakers should 
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carefully assess their current recommendations for NSAID use and adhere to a more unified consensus-
based strategy for multi-disciplinary pain management in elite athletes.  In the future, we hope to see 
more rigorous, prospective studies of various pain management strategies in elite athletes, thus 
enabling a shift from consensus-based recommendations to evidence-based recommendations.   
 
Introduction and Background 
Sports injury is common, and subsequent pain is a normal physiological accompaniment of such injury.  
Pain is defined as, “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”.1  Furthermore, pain can reflect the mechanism of 
injury and be influenced by biopsychosocial factors.  The experience of pain is shaped by 
neurophysiological, cognitive, affective, social, and environmental influences.  Given these complexities, 
and the absence of clear clinical guidelines, pain management strategies vary internationally and often 
do not reflect an understanding of the cause and type of pain experienced by athletes.   
 
Elite athletes, such as professional athletes and athletes competing internationally, likely experience 
pain and pain treatment differently than people undertaking general exercise.2-4 Elite athletes may use 
oral, injectable, and transdermal non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, 
opioids, injectable and trans-dermal anesthetics, as well as cannabinoids, anti-depressants, anxiolytics, 
muscle relaxants, and anti-convulsants.5-8 Furthermore, because of their unique training and 
competition regimens, and their access to specialized medical support, elite athletes may be more likely 
to use multiple agents, receive analgesics from multiple sources, or use analgesics to prevent pain.5, 9-11 
However, efforts to prevent or manage pain solely with medications can increase risk of adverse effects 
while failing to resolve underlying pain conditions.12-15 In addition, some substances used for pain are 
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listed on the World Anti-Doping Agency (WADA) List of Prohibited Substances and Methods, including 
some opioid analgesics and cannabinoids.15  
 
Despite indications that medication use to relieve and prevent pain is widespread among elite athletes,5, 
9, 11, 16-18 there has never been a comprehensive undertaking to identify the usage frequency and effect 
of pain medications among elite athletes. A systematic literature review focused on elite athletes can 
provide a foundation for clearer, more consistent, and evidence-based recommendations regarding 
athletes’ medication use, healthcare professionals’ medication prescribing, and anti-doping policy. 
Therefore, the objective of this study was to conduct a systematic literature review to identify the usage 
frequency and effect of analgesic pain management strategies in elite athletes. This review also served 
as a foundation for some of the key questions examined at the International Olympic Committee’s (IOC) 
2016 Consensus Meeting on Pain Management in Elite Athletes.19  
 
Methods 
We followed the PRISMA guidelines20  to conduct a systematic review of the peer-reviewed literature to 
examine what is currently known about medication for pain management in elite athletes. Our search 
joined three general search concepts: (1) pain or analgesic treatment modalities AND (2) athlete/sport 
AND (3) elite. With this, we aimed to retrieve literature related to the use and effect of medications for 
pain or painful injuries in an elite athlete population. Between February 2 and 14, 2017, we searched six 
literature databases, Ovid/Medline, SPORTDiscus, CINAHL, Embase, Cochrane Library, and Scopus (see 
Appendix for detailed search strategy). This search provided an update to a search we conducted in 
November 2015, which served as a reference to the IOC Consensus Meeting on Pain Management in 
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Elite Athletes. We searched each database using a controlled vocabulary and keywords that represented 
the three general search concepts mentioned above (see Appendix for full syntax). We restricted our 
searches to English language and human studies. We did not restrict to a specific date range. In addition 
to the primary searches, we examined supplemental sources for qualifying articles. These sources 
included the reference lists of systematic review articles returned by our searches. 
 
After retrieving article results for each database and supplemental sources, we conducted an initial 
review of titles and abstracts to identify relevant articles. We used a PICO (Population, Intervention, 
Comparison, Outcome) approach as a starting point for our inclusion criteria, though our review is 
broader and not all included studies simply map to each PICO criterion.21 In particular, our relevant 
Population was elite athletes; relevant Interventions were analgesics or other medications used for pain; 
relevant Comparisons were any; and relevant Outcomes were any outcomes related to prevention or 
treatment of pain or painful injuries. We included empirical studies involving elite (i.e., Olympic, 
Paralympic, professional, collegiate, or other elite) athletes where at least one of the article’s foci was 
on the use, efficacy, or effectiveness of medications used for pain or painful injuries. Studies involving 
“other elite” athletes were those identified by the authors’ using keywords such as “elite” or 
“competitive.” Such studies often involved nationally-recognized athletes, such as those supported by 
national Olympic training programs or youth national teams. However, we also included a small number 
of studies where the authors simply identified study participants as competitive and article context 
suggested involvement of elite athletes. We excluded studies that were not empirical, commentaries, 
non-systematic literature reviews, and studies that included fewer than 10 elite athlete participants. We 
also excluded articles focused on pain medications that are no longer used in humans.  
 
6 
 
Following the initial title and abstract review, we examined the full text of remaining articles to 
determine final inclusion and to code each article for relevant features. Three reviewers first coded a 
20% sub-sample of the total articles and discussed differences to increase subsequent consistency in 
coding. The remaining articles were each coded by a single reviewer. Then, the three coders met as a 
group to review final article inclusion and discuss any uncertainties that arose during individual coding. 
When coding the articles, we extracted the publication year, study design, risks of bias, sample size, 
population (including sport, athlete gender, and athlete country), interventions, type of pain/injury, 
location of pain/injury, duration of pain, study outcomes, and authors’ interpretation of the intervention 
effect (desirable, undesirable, none, unknown, or not applicable). We synthesized results be generating 
summary statistics and qualitative interpretations of the coding results and in-depth article reading.  
 
Results 
Article inclusion 
Our searches found 5,321 total articles, and 4,700 after duplicates were removed (Figure 1). We 
excluded 4,589 articles after reviewing titles and abstracts. We most commonly excluded articles 
because they were not empirical or because they focused on non-athlete or non-elite athlete 
populations. Next, we reviewed the full text of the remaining 111 articles and excluded 49 of those. We 
excluded articles in this final stage because further analysis determined they involved non-elite athletes, 
were non-systematic reviews, were not empirical, did not involve pain medications currently used in 
humans, or were clearly duplicative of articles or data already included. Finally, we included 8 other 
qualifying articles from other sources. Together, this process resulted in a final set of 70 articles for 
analysis.5, 8-11, 16-18, 22-83  
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Overview of studies 
The 70 articles were published between 1975 and 2016. In 20 articles, the athletes studied originated 
from multiple countries. Fourteen articles involved athletes from only the United States of America 
(USA), the most from a single country. Also, multiple studies involved athletes from Argentina, Australia, 
England, Finland, Norway, Germany, and Italy, with other countries represented in a single article only. 
Thirty-two studies involved multiple sports. Sixteen of the single-sport studies involved football (soccer). 
Other sports found in multiple articles include American football, basketball, rugby, cycling, hockey, 
track and field, volleyball, handball, and judo. In terms of athlete level, 25 articles involved professional 
athletes or a mix of professional and other elite athletes. Nine articles involved collegiate or a mix of 
collegiate and other elite athletes. Eleven articles involved Olympic or a mix of Olympic and other elite 
athletes. One article focused solely on Paralympic athletes. The remaining articles focused on other elite 
athletes. Athlete gender was sometimes not specified and could not be clearly inferred from the 
information presented in 15 articles.  However, 23 articles involved only male athletes, and 33 articles 
clearly involved a mix of male and female athletes.  
 
Studies of medication use 
The largest group of included articles (n=45) reported frequency of medication use by athletes across a 
range of sports. Often, these studies described analyses of doping control forms, therapeutic use 
exemptions, pharmacy services, or other reports collected during major sporting events, such as the 
Olympic Games,10, 22, 27-29, 40, 77  Paralympic Games,22, 76 Pan-American games,30, 81 Asian Games,57 and 
Fédération Internationale de Football Association (FIFA) tournaments.11, 17, 18, 26, 58, 75, 80 Other studies 
surveyed collegiate athletes.38, 46, 64, 74, 82 In addition, some studies provided estimates through analysis of 
drug chemistry results (in- or out-of-competition).26-28, 32, 57, 65  
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Oral or non-specific route NSAIDs 
NSAIDs are the most frequently studied and reported to be the most frequently used pain medication. 
Table 1 provides an overview of 25 studies that report oral (or non-specific route) NSAID use rates. We 
were challenged to compare frequencies across all articles because studies reported estimates using 
different techniques and over different time periods, such as in the last 12 months, in season, in the last 
7 days, or during a given competition. Also, articles varied with respect to the mix of sports reported on 
and in the source of the medication data, such as physician prescribed, athlete self-report, laboratory 
testing, or pharmacy records.  On one hand, some articles presented relatively low prevalence of NSAID 
use, including 2.4% of urine samples containing traces of NSAIDs at the 1988 Olympic Winter Games,28 
6.7% of Finnish Olympic athletes prescribed NSAIDs in the last 7 days,22 9.8% of Paralympic athletes who 
declared NSAID use on doping control forms during the Athens 2004 Games,76 and 11.1% of Olympic 
athletes who declared NSAID use on the doping control forms during the Athens 2004 Games.77 On the 
other hand, some articles described relatively high rates of use, including 100% use in non-traumatic 
injuries suffered during an international cycling race (n=16),83 93% use in the past year among Italian 
professional football players,69 over 50% use during the course of an international football 
tournament,11, 17, 18, 75, 80 and 50% use among collegiate American football players over the course of a 
season.38 Studies consistently suggested that NSAID use rates are concerning for myriad reasons, 
including concurrent use of multiple NSAIDs, multiple routes of administration, higher than the 
manufacturer’s recommended dosing, use for prophylaxis of pain, limited evidence-based clinical 
guidance, adverse effects, and limited evidence regarding effects on injury healing.5, 10, 11, 17, 29, 38, 40, 58  
However, some male former athletes may actually be less likely to use NSAIDs when compared with age-
matched controls.43  And, there is some indication that the frequency of NSAID use decreased during the 
2014 FIFA Men’s Football World Cup compared to previous years’ tournaments.80  
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Injectable pain medications 
Compared to oral NSAID use, fewer studies reported on injectable NSAID use. Among Paralympic 
athletes, 9.8% reported using NSAIDs on the doping control forms, with 11.6% of those administered via 
injection.76 Also, 93% of National Football League (NFL) physicians in the USA reported administering 
injectable Ketorolac as often as once per week during the 2000 season, with 21% of teams reporting an 
adverse experience.71 Similarly, across many sports, 79% of American sports medicine physicians 
reported administering injectable Ketorolac to collegiate athletes and 43% reported administering to 
professional athletes, with 12% reporting an adverse reaction.8 Finally, an estimated 31% of football 
players received NSAID injections prior to matches during the 1996 African National Cup.9  
 
Some studies reported injectable anesthetic and/or corticosteroid use. However, like with NSAIDs, the 
approach to measuring and reporting of this practice varied. For example, injectable anesthetics and 
injectable corticosteroid use were sometimes combined and reported in a single use estimate. In other 
studies, injectable and oral corticosteroids were combined and reported in a single use estimate. A 
study of Paralympic athletes reported injectable corticosteroid use in 0.1% of athletes and injectable 
anesthetic use in 1.9% of athletes.76 An estimated 13.5% of hamstring injuries in NFL players are treated 
with injectable corticosteroids.44 During the 2014 FIFA Men’s Football World Cup, team physicians 
reported that 2.6% of athletes used injectable anesthetics and 3.1% used intraarticular or periarticular 
injectable corticosteroids.80 Similarly, between 2.2% and 5.7% of male athletes used either injectable 
anesthetics or injectable corticosteroids at each of the FIFA Futsal World Cup tournaments between 
2002 and 2012.58 
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Opioid analgesic medications 
Most studies that asked athletes about, or tested samples for, opioids reported use rates below 1% of 
athletes.26, 28, 32, 35, 57, 58, 65, 76, 79 A study of pharmacy records from team South Africa during the Athens 
2004 Olympic Games found an average of only 1.54 tablets of opioid-containing analgesics (e.g., 
paracetamol/ibuprofen/codeine) were dispensed per athlete.10 Similarly, few athletes report being 
offered or knowing someone who has used opioids.23 However, one small study reported tramadol use 
in 3.3% of 30 elite cyclists over the previous three months.45  Also, 5.6% of Nigerian professional athletes 
reported using codeine at some point in the past.52  
 
Other medications used for pain 
Reported rates of non-NSAID oral analgesic medications ranged from 0.4% of players at the 2007 under-
20’s World Cup11 to 20% among elite Italian cyclists in the previous three months.45 Often, such 
medication use was reported simply as “analgesic” rather than specifying what types of non-NSAID 
medications, such as paracetamol.  An analysis of over 18,000 doping control forms between 2002 and 
2005, found less than 1% of athletes had used anesthetics, such as lidocaine, in the past three days.79 
Similarly, 1.6% of urine samples analyzed during the 1988 Olympic Winter Games tested positive for 
lidocaine.28  
 
 
Similar to NSAIDs, estimates of corticosteroid use varied, partially due to different approaches to 
measurement. Rates of any corticosteroid use (route of administration not specified further) in the last 
three days as assessed by doping control forms in the mid 2000’s includes estimates between 1%67 and 
6.2% - 9.2%.79 Corticosteroid use among elite cyclists was estimated at 15.8%.34 Surveys of physicians 
about oral corticosteroids, either in or out of competition, found that 83.9% of team physicians 
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prescribe to NFL players,78 and 32% of physicians prescribe to collegiate athletes.46 Finally, three other 
studies of collegiate athletes surveyed use of all non-prescription over-the-counter medications 
combined, including NSAIDs, paracetamol, and others.64, 74, 82 These studies found use of over-the-
counter analgesic medications by 58% to 73% of athletes. These studies also reported athletes lacked 
awareness about adverse effects,74 had significant external influence to use pain medications, and 
frequently misused pain medications,74, 82 especially collegiate American football players.64 
 
Studies assessing effects of medications  
Randomized Controlled Trials 
We reviewed eight randomized controlled trials (RCTs), all but one of which was published in 1990 or 
earlier and had sample sizes of 13-60 athletes (Table 2). Five of the eight RCTs compared the effect of 
two different oral NSAIDs on acute pain when treating various injuries.33, 48-50, 61 Each study included pain 
as a primary outcome, measured by self-report numeric rating or visual analog scale. Secondary 
outcomes including swelling,48 return to sport,49 and physical function.49  These studies all found 
differences in the efficacy of different NSAIDs. Flurbiprofen was more efficacious than aspirin in terms of 
pain reduction and return to play related to acute lower limb soft tissue injuries.50 Furthermore, 
piroxicam was more efficacious than tenoxicam33  and naproxen48  in reducing pain from an acute sport-
related ligament sprain. Piroxicam was also shown to be more efficacious than ibuprofen in reducing 
acute pain and increasing active and passive physical function in athletes with sprains, strains, and other 
soft tissue injuries that had caused functional disability.61 In addition to the RCTs involving oral NSAIDs, 
one study of collegiate athletes found diflusinal, a salicylic acid derivate, was equally efficacious in 
reducing pain, tenderness, and swelling due to acute injury as paracetamol combined with codeine.41   
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The most recent RCT, from 2006, examined elite athletes with chronic patellar tendinopathy and found 
sclerosing injections of polidocanol to be more effective in improving pain scores and function 
assessments than lidocaine with epinephrine injections.36  Finally, one RCT compared the effect of 
naloxone versus placebo in non-injured athletes.66 The study found weak evidence to suggest that 
naloxone may reduce affective components of pain but not sensory, evaluative, supplemental, or overall 
pain intensity.84 
 
Observational studies 
Twelve of 14 observational studies evaluated the effects of non-NSAID injectable therapies, which 
included corticosteroid injections,39, 42, 44, 68 injectable or local anaesthetics,51, 53, 54, 62 and, in chronic 
situations, regenerative dextrose injections,72, 73  and sclerosing injections24, 37  (Table 3). These studies 
focused on groin pain,39, 51, 62, 72, 73 hamstring injury,44, 68 lumbar disc herniation,42 patellar 
tendinopathy,24, 37  or a mix of injuries and pain.53, 54 Four studies reported on acute pain or injury.39, 42, 53, 
62 Four studies reported on either chronic pain or chronic and subacute pain combined.24, 68, 72, 73 Four 
studies were non-specific about pain chronicity.37, 44, 51, 54 The majority of the studies concluded there 
were positive effects of the primary therapy on reduction of pain or related outcomes. Studies finding 
negative or null results often suggested the need to evaluate the risks and benefits of the therapies on a 
case-by-case basis. However, in terms of study design, none of the studies of injectable medications 
used a control group, which may bias their conclusions. Furthermore, these studies had a mean sample 
size of 55. Seven of 12 studies had samples of less than 30, including several case series.  The two largest 
studies (N ≥ 100 treated injuries) each retrospectively examined the effects, including complications, 
associated with injectable therapies for analgesia. In one study of 1,023 local anesthetic injections 
recorded in a cohort of 100 players, 73% of athletes perceived the therapy as helpful. But, 22% thought 
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the injury took longer than expected to recover and 6% thought the injury worsened.54 The other study 
examined 268 injuries treated with anesthetics (221 injection, 47 topical). Among these, there were 11 
minor and 6 major complications.53 
 
In addition to the injectable analgesic therapy observational studies, one study examined 28 Australian 
football players who received intranasal sumatriptan for moderate-to-severe acute headaches (both 
migraine and non-migraine). The study found that symptoms resolved or became mild in 86% of 
headaches within two hours of taking sumatriptan.47 Another qualitative study interviewed 36 
breaststroke swimmers about chronic knee pain and concluded that NSAIDs may be useful in reducing 
symptoms of knee pain.60 
 
Studies of attitudes toward pain medications 
Four studies assessed elite athletes’ knowledge of and attitudes toward pain medication use, either in 
the broader context of drug use in sports23, 55, 56  or in the context of playing with injuries.59  A survey of 
446 Finnish athletes on banned substances found that 13.8% of athletes believed narcotic analgesics 
have performance-enhancing effects; 1.2% said narcotic analgesics had been offered to them, but only 
0.5% claimed to know athletes who used these substances.23 In a series of 11 interviews, elite amateur 
cyclists described regular use of NSAIDs in combination with caffeine.55 Pan et al. surveyed collegiate 
athletes on their attitudes toward 16 banned substances, including morphine. The study found female 
athletes, more than male athletes, perceived morphine as having some athletic relevance, functional 
benefits, and some dysfunctional effects.56  Finally English professional football players, club doctors, 
and club physiotherapists all described enormous pressures to avoid missing matches due to injury. 
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They reported injectable analgesic use was related to guilt over missing matches, fear of losing a roster 
spot, and desire to reach minimum game appearance thresholds to achieve additional pay.59 
 
Discussion 
We identified and reviewed 70 studies related to pain medications and elite athletes. One important 
finding was that the majority of the literature describes frequency of pain medication use rather than 
assessing the effects of pain medications on health-related outcomes. Thus, the majority of the 
literature directly assessing analgesic use in elite athletes has limited use in directly helping sports 
healthcare professionals make evidence-based treatment choices relating to pain medications.  A 
second finding was that studies that do assess pain medication efficacy or adverse effects are often 
several decades old and have unreliable methodologies, including small sample size and lack of control 
groups, which can contribute to bias in the findings. These weaknesses prevent us from making 
literature-driven policy or treatment recommendations about pain medication use in elite athletes.  
 
The specific finding with the most empirical support is the widespread use of NSAIDs among elite 
athletes. Nearly every study that measured use frequency of different pain medications indicated 
NSAIDs were the most frequently used medication.  In football (soccer) in particular, several studies that 
include data from several international tournaments report in-tournament oral NSAID use among at 
least 30% of athletes, and in some tournaments more than 50% of athletes. These use rates tend to be 
much lower than estimates of other pain medication use, including other oral analgesics and injectable 
NSAIDs, anesthetics, and corticosteroids. These studies do not empirically assess the risks or benefits 
associated with NSAID use, though studies in general populations and non-elite athletes have identified 
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health risks related to NSAID use.14, 85-87  Thus, in the studies we reviewed, the articles’ authors 
frequently question the safety of observed NSAID rates of use. Without specific data, the articles also 
raise concerns about unsafe patterns of use, such as use of multiple concurrent NSAID use, multiple 
routes of administration, high dosing, and inappropriate use for pain prophylaxis. Thus, an important 
area of future study is to develop more rigorous quantitative understanding of the patterns of NSAID 
use in elite athletes and potential associated health risks. 
 
Varying approaches to estimating analgesic medication use rates made it difficult to make precise 
comparisons of frequency of use across studies. For example, some studies, such as those relying on 
doping control data, estimate use based on athlete-reported use in recent days. Other studies survey 
athletes out of competition and ask about use over longer time periods, such as the past year. Still other 
studies measured pharmacy dispensing or physician reports of their prescribing of certain medications 
to elite athletes. Thus, we were unable to make reliable comparisons about use rates, such as over time, 
across sports, or between different sub-populations of elite athletes. Future research that aims to more 
reliably compare use rates should consider adopting previously used questionnaires or other 
measurement methods. We recognize this is challenging when studies often rely on secondary data. 
Still, future research would benefit from increased consistency in data collection and approaches to 
measuring and reporting medication use.  
 
A minority of studies reviewed actually examined outcomes of medication use for pain. Furthermore, 
the literature contains very few RCTs, the most rigorous of research designs. Of the RCTs found, only 
one was published in the last 25 years. Perhaps owing to challenges of recruiting elite athletes, the RCTs 
also tended to be conducted on small samples. Thus, we question the generalizability of these results to 
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today’s elite athletes. The observational studies found tended to be published more recently and to 
focus on the effects of injectable pain medications.  These studies’ tended to report positively on the 
effect of injection therapies in having minimal complications, reducing pain, improving function, and 
helping athletes return to play.  However, the validity of these results should be interpreted cautiously 
due to their tendency to be based on small samples and their lack of control groups. Again, while we 
recognize practical challenges, future research would benefit from more RCTs and more rigorous 
retrospective research on pain medications and health outcomes. Such research may benefit from 
developing or using existing research registries, electronic health record data sources, identifying control 
groups, and using advanced statistical methods to further control for unobserved differences when 
comparing athletes who received different treatments. 
Our findings suggest some sports and athletes that can be targeted with interventions to prevent 
analgesic misuse or adverse effects.  First, several studies reported relatively high levels of NSAID use 
among football players,11, 17, 18, 69, 75, 80 and pressure to use medications to return to play.59 Therefore, 
national and international football organizations might consider increasing education and other 
interventions to mitigate NSAID risks among their constituent athletes. Second, studies reported 
relatively high analgesic use among collegiate athletes,8, 38, 64, 74, 82 as well as poor awareness and 
perceived pressure to use medications.64, 74, 82 As a result, collegiate and younger athletes generally may 
also be an important group to better educate about safe analgesic use and effective pain management. 
 
One limitation of this study is that it does not reflect research on pain management in non-elite athletes.  
However, in this study, we chose a more focused approach that considered elite athletes a distinct 
group with different needs, pressures, and treatments relative to injury and pain. With this approach, 
we aimed to summarize evidence that would be most generalizable to elite athletes. A second limitation 
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of this study is the potential for inaccurate article inclusion or exclusion based on the study population 
(i.e., elite or non-elite). To mitigate this limitation and apply a consistent identification approach, we 
used multiple coders and group discussion to resolve disagreement. Also, given our interest in elite 
athletes, we applied a conservative standard for inclusion, thereby excluding articles for which the 
population was unclear. Last, we reviewed many studies that varied in their approach to measuring and 
reporting medication use frequency. As a consequence, our review was unable to quantitatively 
summarize medication use frequency across studies. Similarly, we found few studies that focused on 
medication effects and attitudes towards medication use, and many studies we found had small sample 
sizes. This also limited our ability to quantitatively summarize prior work. 
Conclusion 
Existing empirical research does not provide a sufficient body of evidence to guide athletes and 
healthcare professionals in making analgesic medication treatment decisions. Based on the relatively 
robust evidence regarding the widespread use of NSAIDs, clinicians and policymakers should carefully 
assess their current recommendations for NSAID use and adhere to a more unified consensus-based 
strategy for multi-disciplinary pain management in elite athletes.  Our hope is that this article and 
related work will kindle a more rigorous, prospective assessment of various pain management strategies 
in elite athletes, thus enabling a shift from consensus-based recommendations to evidence-based 
recommendations.   
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Figure Legend 
Figure 1: Flow diagram showing process if identifying, screening, assessing eligibility and including 
final articles for review 
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final articles for review 
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Table 1. Overview of Articles Reporting Oral (or Non-specific Route) NSAID Use Frequency 
Article 
Year First Author Title Sport Country 
1989 Wagner, J.D. Pharmaceutical services at the Tenth Pan American Games Multiple Various 
1991 Chan, S.C. Drug analysis at the 1988 Olympic Winter Games in Calgary Multiple Various 
2003 Corrigan, B. Medication use in athletes selected for doping control at the Sydney Olympics (2000) Multiple Various 
2003 Kujala, U.M. Use of medications and dietary supplements in later years among male former top-level athletes Multiple Finland 
2006 Alaranta, A. Ample use of physician-prescribed medications in Finnish elite athletes Multiple Finland 
2006 Huang, S. The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games Multiple Canada 
2007 Taioli, E. Use of permitted drugs in Italian professional soccer players Football (Soccer) Italy 
2008 Derman, W.E. Medication use by Team South Africa during the XXVIIIth Olympiad: A model for quantity estimation for multi-coded team events Multiple South Africa 
2008 Tscholl P. The use of medication and nutritional supplements during FIFA World Cups 2002 and 2006 
Football 
(Soccer) Various 
2008 Van Thuyne, W. Declared use of medication in sports Multiple Netherlands, Belgium 
2009 Tscholl, P. The use and abuse of painkillers in international soccer: data from 6 FIFA tournaments for female and youth players 
Football 
(Soccer) Various 
2009 Tsitsimpikou, C. Medication use by athletes at the Athens 2004 Summer Olympic Games Multiple Various 
2009 Tsitsimpikou, C. Medication use by athletes during the Athens 2004 Paralympic Games Multiple Various 
2010 Tscholl, P. The use of drugs and nutritional supplements in top-level track and field athletes Track & Field Various 
2011 Da Silva, E.R. Non-steroidal anti-inflammatory use in the XV Pan-American Games (2007) Multiple Various 
2011 Lazic, J.S. Dietary supplements and medications in elite sport – polypharmacy or real need? Multiple Various 
2012 de Souza Almeida, F. 
Muscle lesion treatment in Brazilian soccer players: Theory vs. 
Practice 
Football 
(Soccer) Brazil 
2012 Tscholl, P. Abuse of medication during international football competition in 2010 – lesson not learned 
Football 
(Soccer) Various 
2013 Aavikko, A. Physician-prescribed medication use by the Finnish Paralympic and Olympic athletes Multiple Finland 
2013 Holmes, N. Nonsteroidal anti-inflammatory drug use in collegiate football players 
American 
Football United States 
2014 Loraschi, A. Dietary supplement and drug use and doping knowledge and attitudes in Italian young elite cyclists Cycling Italy 
2015 Pedrinelli, A. Medications and nutritional supplements in athletes during the 2000, 2004, 2008, and 2012 FIFA Futsal World Cups 
Football 
(Soccer) Various 
2015 Tscholl, P. 
High prevalence of medication use in professional football 
tournaments including the World Cups between 2002 and 2014: a 
narrative review with a focus on NSAIDs 
Football 
(Soccer) Various 
2015 Vaso, M. Use and abuse of medication during 2014 FIFA World Cup Brazil: a retrospective survey 
Football 
(Soccer) Various 
2015 Yanturali, S. Injury and illness among athletes during a multi-day elite cycling road race Cycling Various 
Note: All studies were observational. Data sources included surveys, pharmacy records, laboratory tests, doping control form analyses, and 
therapeutic use exemption analyses. Specific use rate estimates are not reported due to widely varying methods eliciting and reporting use. 
 
 
 
 
 
  
Table 2. Overview of Randomised Controlled Trials of Medication Interventions for Pain 
Year First Author Title Sport 
Sample 
Size Intervention 1 Intervention 2 Outcome(s)  
1975 Muckle, D.S. 
Section 1 ibuprofen ('Brufen') in 
soft-tissue injuries 
Football 
(soccer) 
60 
NSAID oral: 
ibuprofen 
NSAID oral: 
aspirin 
Pain, Return to sport 
1976 Muckle, D.S. 
A comparative study of flurbiprofen 
and aspirin in soft tissue trauma 
Football 
(soccer) 
52 
NSAID oral: 
flurbiprofen 
NSAID oral: 
aspirin 
Pain, Return to sport 
1980 Santilli, G. 
Comparative study with piroxicam 
and ibuprofen versus placebo in the 
supportive treatment of minor 
sports injuries 
Multiple 30 
NSAID oral: 
piroxicam 
NSAID oral: 
ibuprofen 
Pain, Function 
1984 Surbey, G.D. 
Effects of naloxone on exercise 
performance 
Track 
(middle 
distance) 
13 
 
Naloxone Placebo 
Vitals (O2 uptake, heart 
rate, ventilation), 
Perceived exertion, 
Pain perception 
1986 Indelicato, P.A. 
Comparison of diflunisal and 
acetaminophen with codeine in the 
treatment of mild to moderate pain 
due to strains and sprains 
American 
Football 
50 
NSAID oral: 
diflunisal 
Other analgesic: 
Paracetamol and 
codeine 
Pain, Musculoskeletal 
swelling 
1988 McIlwain, H.H. 
Piroxicam versus naproxen in the 
treatment of acute musculoskeletal 
disorders in athletes 
Multiple 34 
NSAID oral: 
piroxicam 
NSAID oral: 
naproxen 
Pain, Musculoskeletal 
damage/deformity 
1990 Galasso, G. 
Analgesic activity of beta-
cyclodextrin-piroxicam and 
tenoxicam in acute soft tissue 
injuries 
Football 
(soccer) 
49 
NSAID oral: 
Piroxicam 
NSAID oral:  
tenoxicam 
Prevalence of pain 
2006 Hoksrud, A.  
Ultrasound-guided sclerosis of 
neovessels in painful chronic 
patellar tendinopathy: a 
randomized controlled trial 
Multiple 43 
Polidocanol 
injection 
Lidocaine/epine
phrine injection 
Pain, Function 
 
  
Table 3. Overview of Observation Studies of Medication Interventions for Pain 
Year First Author Title Sport 
Sample 
Size Intervention Outcome(s) 
1985 Rovere, G.D. Frequency, associated factors, and treatment of breaststroker's knee in competitive swimmers Swimming 36 NSAID Pain 
1995 Holt, M.A. Treatment of osteitis pubis in athletes. Results of corticosteroid injections Multiple 12 
Corticosteroid 
injection 
Return to 
sport 
2000 Levine, W.N. 
Intramuscular corticosteroid injection for hamstring 
injuries. A 13-year experience in the National Football 
League 
American 
football 58 
Corticosteroid 
injection 
Complications, 
Return to 
sport 
2002 Orchard, J.W. Benefits and risks of using local anaesthetic for pain relief to allow early return to play in professional football Multiple 268 
Local anaesthetic 
injection or topical Complications 
2002 O'Connell, M.J. Symphyseal cleft injection in the diagnosis and treatment of osteitis pubis in athletes Multiple 16 
Local anaesthetic and 
steroid injection 
Pain, Return to 
sport 
2005 McCrory, P. Open label study of intranasal sumatriptan (Imigran) for footballer's headache 
Football 
(soccer) 38 
intranasal 
sumatriptan Pain 
2005 Alfredson, H. 
Neovascularisation in chronic painful patellar tendinosis-
promising results after sclerosing neovessels outside the 
tendon challenge the need for surgery 
Multiple 15 sclerosing injection Pain 
2005 Topol, G.A. Efficacy of dextrose prolotherapy in elite male kicking-sport athletes with chronic groin pain Multiple 24 Dextrose injection Pain, Function 
2005 Szalai, K. Sacral epidural steroid injections used for the prevention of hamstring injuries Multiple 25 
Epidural steroid 
injection 
Pain Recovery 
time 
2007 Schilders, E. 
Adductor-related groin pain in competitive athletes. Role 
of adductor enthesis, magnetic resonance imaging, and 
entheseal pubic cleft injections 
Multiple 24 Local anaesthetic and steroid injection 
Pain, 
Recurrence 
2008 Topol, G.A. 
Regenerative injection of elite athletes with career-
altering chronic groin pain who fail conservative 
treatment: A consecutive case series 
Multiple 72 Dextrose injection Pain, Return to sport 
2008 Hoksrud, A. Color doppler ultrasound findings in patellar tendinopathy (jumper's knee) Multiple 63 sclerosing injection Function 
2010 Orchard, J.W. Long-term safety of using local anesthetic injections in professional rugby league Rugby 100 
Local anaesthetic 
injection 
Satisfaction;, 
Complications 
2012 Krych, A.J. Epidural steroid injection for lumbar disc herniation in NFL athletes 
American 
football 17 
Epidural steroid 
injection 
Return to 
sport 
 
Appendix.  Detailed Search Strategy 
Database Search 
OVID 1. olympi*.mp. 
2. compet*.mp. 
3. premier.mp. 
4. 'high level'.mp. 
5. colleg*.mp. 
6. professional*.mp. 
7. "major league".mp.  
8. "elite".mp.  
9. "top-level".mp.  
10. "world-class".mp.  
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10  
12. athlet*.mp.  
13. exp sports medicine/  
14. exp sport/ 
15. exp exercise/  
16. exp athletic injuries/ 
17. sport*.mp. 
18. player*.mp. 
19. 12 or 13 or 14 or 15 or 16 or 17 or 18 
20. exp analgesics/ 
21. nsaid*.mp. 
22. opioid*.mp.  
23. exp acetaminophen/ 
24.  exp aspirin/  
25. exp "Anesthesia and Analgesia"/ 
26. exp Anti-Inflammatory Agents/  
27. exp narcotics/ 
28. exp pain/ 
29. exp pain management/ 
30. exp prescription drug misuse/ 
31.  (Alfentanil or Alphaprodine or Buprenorphine or 
Butorphanol or Codeine or Dextromoramide or 
Dextropropoxyphene or Dihydromorphine or 
Diphenoxylate or Enkephalin Ala 2-MePhe 4-Gly 5 or 
Enkephalin, D-Penicillamine 2,5 or Ethylketocyclazocine 
or Ethylmorphine or Etorphine or Fentanyl or Heroin or 
Hydrocodone or Hydromorphone or Levorphanol or 
Meperidine or Meptazinol or Methadone or Methadyl 
Acetate or Morphine or Nalbuphine or Opiate Alkaloid$ 
or Opium or Oxycodone or Oxymorphone or Pentazocine 
or Phenazocine or Phenoperidine or Pirinitramide or 
Promedol or Sufentanil or Tilidine or Tramadol or 
pethidine or dihydrocodeine).mp. 
32.  (4,5-Dihydro-1-3-trifluoromethyl phenyl 1H-pyrazol-3-
amine or Ampyrone or Antipyrine or Apazone or Aspirin 
or Bufexamac or Clonixin or Curcumin or Diclofenac or 
Diflunisal or Dipyrone or Epirizole or Fenoprofen or 
Feprazone or Flurbiprofen or Ibuprofen or Indomethacin 
or Ketoprofen or Ketorolac or Ketorolac Tromethamine or 
Meclofenamic Acid or Mefenamic Acid or Mesalamine or 
Naproxen or Niflumic Acid or Oxyphenbutazone or 
Phenylbutazone or Piroxicam or Salicylates or Sodium 
Salicylate or Sulfasalazine or Sulindac or Suprofen or 
Tolmetin).mp. 
33. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 
30 or 31 or 32 
34. 11 and 19 and 33 
35. limit 34 to (english language and humans) 
CINHAL 1. olympi* OR compet* OR premier OR "high level" OR 
colleg* OR professional* OR "major league" OR elite OR 
"top-level" OR "world-class" 
2. (sport* or player*) or MH athletes or MH "sports 
medicine" or MH SPORTS  
3. "ANALGESICS" OR "ACETAMINOPHEN" OR 
"ANTIPYRETICS" OR "CLONIDINE" OR "DIMETHYL 
sulfoxide" OR "FLURBIPROFEN" OR "IBUPROFEN" OR 
"OXYCODONE"  
4. "NONSTEROIDAL anti-inflammatory agents" OR 
"ASPIRIN" OR "FLURBIPROFEN" OR "IBUPROFEN" OR 
"INDOMETHACIN" OR "KETOROLAC (Drug)" OR 
"NAPROXEN" OR "PHENYLBUTAZONE" OR "PIROXICAM"  
5. "ANESTHESIA" OR "CONDUCTION anesthesia" 
6. "ANALGESIA" OR "TRANSCUTANEOUS electrical nerve 
stimulation"  
7. MH "ANTI-inflammatory agents" OR MH "DICLOFENAC" 
OR MH "DIMETHYL sulfoxide" OR MH 
"GLUCOCORTICOIDS" OR MH "NONSTEROIDAL anti-
inflammatory agents"  
8. MH "NARCOTICS" OR MH "COCAINE" OR MH "HASHISH" 
OR MH "HEROIN" OR MH "MORPHINE" OR MH 
"OXYCODONE"  
9. MH "PAIN" OR "ABDOMINAL pain" OR "BACKACHE" OR 
"CENTRAL pain" OR "CHEST pain" OR "CHRONIC pain" OR 
"COMPLEX regional pain syndromes" OR "EARACHE" OR 
"ELBOW pain" OR "FACIAL pain" OR "FOOT pain" OR 
"GROIN pain" OR "HEADACHE" OR "INTRACTABLE pain" 
OR "KNEE pain" OR "LEG pain" OR "MYALGIA" OR 
"MYOFASCIAL pain syndromes" OR "NECK pain" OR 
"PAIN management" OR "PAIN measurement" OR 
"PELVIC pain" OR "SHOULDER pain" OR "SIDE stitch"  
10. "nsaid*" OR "opioid*" OR ( (Alfentanil or Alphaprodine 
or Buprenorphine or Butorphanol or Codeine or 
Dextromoramide or Dextropropoxyphene or 
Dihydromorphine or Diphenoxylate or Enkephalin Ala 2-
MePhe 4-Gly 5 or Enkephalin, D-Penicillamine 2,5 or 
Ethylketocyclazocine or Ethylmorphine or Etorphine or 
Fentanyl or Heroin or Hydrocodone or Hydromorphone 
or Levorphanol or Meperidine or Meptazinol or 
Methadone or Methadyl Acetate or Morphine or 
Nalbuphine or Opiate Alkaloid$ or Opium or Oxycodone 
or Oxymorphone or Pentazocine or Phenazocine or 
Phenoperidine or Pirinitramide or Promedol or 
Sufentanil or Tilidine or Tramadol or pethidine or 
dihydrocodeine) ) OR ( (4,5-Dihydro-1-3-trifluoromethyl 
phenyl 1H-pyrazol-3-amine or Ampyrone or Antipyrine or 
Apazone or Aspirin or Bufexamac or Clonixin or Curcumin 
or Diclofenac or Diflunisal or Dipyrone or Epirizole or 
Fenoprofen or Feprazone or Flurbiprofen or Ibuprofen or 
Indomethacin or Ketoprofen or Ketorolac or Ketorolac 
Tromethamine or Meclofenamic Acid or Mefenamic Acid 
or Mesalamine or Naproxen or Niflumic Acid or 
Oxyphenbutazone or Phenylbutazone or Piroxicam or 
Salicylates or Sodium Salicylate or Sulfasalazine or 
Sulindac or Suprofen or Tolmetin) )  
11. S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 
12. S1 AND S2 AND S11 
13. Academic Journals 
SportDISCUS 1. SU "OLYMPIC athletes" OR SU "WOMEN Olympic 
athletes" OR SU "ELITE athletes" OR SU "PROFESSIONAL 
athletes" OR SU "AFRICAN American professional 
athletes" OR SU "FREE agents (Sports)" OR SU "LGBT 
professional athletes" OR SU "WOMEN professional 
athletes" OR SU "COLLEGE athletes" OR SU "COLLEGE 
basketball players" OR SU "COLLEGE football players" OR 
SU "COMMUNITY college athletes" OR SU "MALE college 
athletes" OR SU "SEXUAL minority college athletes" OR 
SU "WOMEN college athletes"  
2. olympi* OR compet* OR premier OR "high level" OR 
colleg* OR professional* OR "major league" OR elite OR 
"top-level" OR "world-class"  
3. S1 OR S2 
4. "ANALGESICS" OR "ACETAMINOPHEN" OR 
"ANTIPYRETICS" OR "CLONIDINE" OR "DIMETHYL 
sulfoxide" OR "FLURBIPROFEN" OR "IBUPROFEN" OR 
"OXYCODONE"  
5. "NONSTEROIDAL anti-inflammatory agents" OR "ASPIRIN" 
OR "FLURBIPROFEN" OR "IBUPROFEN" OR 
"INDOMETHACIN" OR "KETOROLAC (Drug)" OR 
"NAPROXEN" OR "PHENYLBUTAZONE" OR "PIROXICAM"  
6. "OPIOIDS" OR "OXYCODONE"  
7. "ANESTHESIA" OR "CONDUCTION anesthesia" 
8. "ANALGESIA" OR "TRANSCUTANEOUS electrical nerve 
stimulation"  
9. "nsaid*" OR "opioid*" OR ( (Alfentanil or Alphaprodine or 
Buprenorphine or Butorphanol or Codeine or 
Dextromoramide or Dextropropoxyphene or 
Dihydromorphine or Diphenoxylate or Enkephalin Ala 2-
MePhe 4-Gly 5 or Enkephalin, D-Penicillamine 2,5 or 
Ethylketocyclazocine or Ethylmorphine or Etorphine or 
Fentanyl or Heroin or Hydrocodone or Hydromorphone 
or Levorphanol or Meperidine or Meptazinol or 
Methadone or Methadyl Acetate or Morphine or 
Nalbuphine or Opiate Alkaloid$ or Opium or Oxycodone 
or Oxymorphone or Pentazocine or Phenazocine or 
Phenoperidine or Pirinitramide or Promedol or Sufentanil 
or Tilidine or Tramadol or pethidine or dihydrocodeine) ) 
OR ( (4,5-Dihydro-1-3-trifluoromethyl phenyl 1H-pyrazol-
3-amine or Ampyrone or Antipyrine or Apazone or Aspirin 
or Bufexamac or Clonixin or Curcumin or Diclofenac or 
Diflunisal or Dipyrone or Epirizole or Fenoprofen or 
Feprazone or Flurbiprofen or Ibuprofen or Indomethacin 
or Ketoprofen or Ketorolac or Ketorolac Tromethamine or 
Meclofenamic Acid or Mefenamic Acid or Mesalamine or 
Naproxen or Niflumic Acid or Oxyphenbutazone or 
Phenylbutazone or Piroxicam or Salicylates or Sodium 
Salicylate or Sulfasalazine or Sulindac or Suprofen or 
Tolmetin) ) 
10. S4 OR S5 OR S6 OR S7 OR S8 OR S9 
11. S3 AND S10 
12. Academic journals 
Embase 1. 'athlete'/exp OR athlete.tw OR 'sports           
medicine'/exp OR 'sports medicine.tw' OR 'sport'/exp OR 
sport.tw OR player*.tw 
2. 'olympic team' OR 'olympics' OR 'olympia' OR compet*.tw 
OR premier OR 'high-level' OR colleg*.tw OR 
professional*.tw OR 'major league' OR elite OR 'top-level' 
OR 'world-class' 
3. 'analgesic'/exp OR 'narcotic agent'/exp OR         
'anesthesia'/exp OR 'anti inflammatory agent'/exp OR 
'narcotic analgesic'/exp OR 'pain'/exp OR 'opioid'/exp OR 
'nonsteroidal antiinflammatory agent'/exp 
4. alfentanil OR alphaprodine OR buprenorphine OR         
butorphanol OR codeine OR dextromoramide OR  
dextropropoxyphene OR dihydromorphine OR  
diphenoxylate OR 'enkephalin ala 2-mephe 4-gly 5' OR 
'enkephalin, d-penicillamine 2,5' OR ethylketocyclazocine 
OR ethylmorphine OR etorphine OR fentanyl OR heroin 
OR hydrocodone OR hydromorphone OR levorphanol OR 
meperidine OR meptazinol OR methadone OR 'methadyl 
acetate' OR morphine OR nalbuphine OR 'opiate alkaloid' 
OR opium OR oxycodone OR oxymorphone OR 
pentazocine OR phenazocine OR phenoperidine OR 
pirinitramide OR promedol OR sufentanil OR tilidine OR 
tramadol OR pethidine OR dihydrocodeine OR '4,5-
dihydro-1-3-trifluoromethyl phenyl 1h-pyrazol-3-amine' 
OR ampyrone OR antipyrine OR apazone OR aspirin OR 
bufexamac OR clonixin OR curcumin OR diclofenac OR 
diflunisal OR dipyrone OR epirizole OR fenoprofen OR 
feprazone OR flurbiprofen OR ibuprofen OR 
indomethacin OR ketoprofen OR ketorolac OR 'ketorolac 
tromethamine' OR 'meclofenamic acid' OR 'mefenamic 
acid' OR mesalamine OR naproxen OR 'niflumic acid' OR 
oxyphenbutazone OR phenylbutazone OR piroxicam OR 
salicylates OR 'sodium salicylate' OR sulfasalazine OR 
sulindac OR suprofen OR tolmetin 
5. (1 AND 2 AND (3 OR 4))AND [humans]/lim AND 
[english]/lim 
Cochrane 1. MeSH descriptor: [Analgesics] explode all trees 
2. MeSH descriptor: [Acetaminophen] explode all trees 
3. MeSH descriptor: [Aspirin] explode all trees 
4. MeSH descriptor: [Anesthesia and Analgesia] explode all 
trees 
5. MeSH descriptor: [Anti-Inflammatory Agents] explode all 
trees 
6. MeSH descriptor: [Narcotics] explode all trees 
7. MeSH descriptor: [Pain] explode all trees 
8. MeSH descriptor: [Pain Management] explode all trees 
9. NSAID* 
10. opioid* 
11. (alfentanil or alphaprodine or buprenorphine or 
butorphanol or codeine or dextromoramide or 
dextropropoxyphene or dihydromorphine or 
diphenoxylate or "Enkephalin Ala 2-MePhe 4-Gly 5" or 
"Enkephalin, D-Penicillamine 2,5" or ethylketocyclazocine 
or ethylmorphine or etorphine or fentanyl or heroin or 
hydrocodone or hydromorphone or levorphanol or 
meperidine or meptazinol or methadone or Methadyl 
Acetate or morphine or nalbuphine or Opiate Alkaloid or 
opium or oxycodone or oxymorphone or pentazocine or 
phenazocine or phenoperidine or pirinitramide or 
promedol or sufentanil or tilidine or tramadol or 
pethidine or dihydrocodeine or "4,5-Dihydro-1-3-
trifluoromethyl phenyl 1H-pyrazol-3-amine" or ampyrone 
or antipyrine or apazone or aspirin or bufexamac or 
clonixin or curcumin or diclofenac or diflunisal or 
dipyrone or epirizole or fenoprofen or feprazone or 
flurbiprofen or ibuprofen or indomethacin or ketoprofen 
or ketorolac or "Ketorolac Tromethamine" or 
Meclofenamic Acid or "Mefenamic Acid" or mesalamine 
or naproxen or "Niflumic Acid" or oxyphenbutazone or 
phenylbutazone or piroxicam or salicylates or Sodium 
Salicylate or sulfasalazine or sulindac or suprofen or 
tolmetin)   
12. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 
or #11   
13. MeSH descriptor: [Athletes] explode all trees  
14. MeSH descriptor: [Sports Medicine] explode all trees  
15. MeSH descriptor: [Sports] explode all trees  
16. MeSH descriptor: [Athletic Injuries] explode all trees  
17. player*  
18. (#13 or #14 or #15 or #16 or #17)   
19. olympi* or compet* or premier or "high-level" or colleg* 
or professional* or "major-league" or elite or "top-level" 
or "world-class":ti,ab,kw  (Word variations have been 
searched)  
20. #12 and #18 and #19 
Scopus ( TITLE-ABS-KEY ( olympi*  OR  compet*  OR  premier  OR  {high 
level}  OR  colleg*  OR  professional*  OR  {major league}  OR  elite  
OR  {top-level}  OR  {world-class} ) )  AND  ( TITLE-ABS-KEY ( 
athlet*  OR  "sports medicine"  OR  sport  OR  "athletic injuries"  
OR  player* ) )  AND  ( ALL ( alfentanil  OR  alphaprodine  OR  
buprenorphine  OR  butorphanol  OR  codeine  OR  
dextromoramide  OR  dextropropoxyphene  OR  dihydromorphine  
OR  diphenoxylate  OR  "Enkephalin Ala 2-MePhe 4-Gly 5"  OR  
"Enkephalin, D-Penicillamine 2,5"  OR  ethylketocyclazocine  OR  
ethylmorphine  OR  etorphine  OR  fentanyl  OR  heroin  OR  
hydrocodone  OR  hydromorphone  OR  levorphanol  OR  
meperidine  OR  meptazinol  OR  methadone  OR  "Methadyl 
Acetate"  OR  morphine  OR  nalbuphine  OR  "Opiate Alkaloid*"  
  
 
OR  opium  OR  oxycodone  OR  oxymorphone  OR  pentazocine  
OR  phenazocine  OR  phenoperidine  OR  pirinitramide  OR  
promedol  OR  sufentanil  OR  tilidine  OR  tramadol  OR  
pethidine  OR  dihydrocodeine  OR  "4,5-Dihydro-1-3-
trifluoromethyl phenyl 1H-pyrazol-3-amine"  OR  ampyrone  OR  
antipyrine  OR  apazone  OR  aspirin  OR  bufexamac  OR  clonixin  
OR  curcumin  OR  diclofenac  OR  diflunisal  OR  dipyrone  OR  
epirizole  OR  fenoprofen  OR  feprazone  OR  flurbiprofen  OR  
ibuprofen  OR  indomethacin  OR  ketoprofen  OR  ketorolac  OR  
"Ketorolac Tromethamine"  OR  "Meclofenamic Acid"  OR  
"Mefenamic Acid"  OR  mesalamine  OR  naproxen  OR  "Niflumic 
Acid"  OR  oxyphenbutazone  OR  phenylbutazone  OR  piroxicam  
OR  salicylates  OR  "Sodium Salicylate"  OR  sulfasalazine  OR  
sulindac  OR  suprofen  OR  tolmetin  OR  analgesics  OR  
acetaminophen  OR  aspirin  OR  anesthesia  AND  analgesia  OR  
anti-inflammatory  AND agents  OR  narcotics  OR  pain  OR  nsaid  
OR  opioid* ) )  AND  ( LIMIT-TO ( LANGUAGE ,  "English" ) )  AND  ( 
LIMIT-TO ( EXACTKEYWORD ,  "Human" )  OR  LIMIT-TO ( 
EXACTKEYWORD ,  "Humans" ) )  
